Jiangsu Hansoh Pharmaceutical Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS20
PHASE 3 / 2-312
RECRUITING6
READOUTS ≤12 MONTHS6
READOUT SLIPPED >6 MO0%
Delay Index: of 5 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Jiangsu Hansoh Pharmaceutical Co., Ltd. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Aumolertinib NCT04923906 |
P3 | Active, not recruiting | Non-small Cell Lung Cancer | 624 | 2024-06-18 (+5 mo) |
| Almonertinib NCT04687241 |
P3 | Active, not recruiting | Non-small Cell Lung Cancer | 192 | 2024-07-08 |
| Almonertinib NCT04951635 |
P3 | Recruiting | Non-small Cell Lung Cancer | 150 | 2024-07-15 |
| HS-10561 NCT06864507 |
P1/2 | Not yet recruiting | Chronic Spontaneous Urticaria | 150 | 2026-09-27 |
| HS-20118 NCT07765628 |
P2 | Not yet recruiting | Moderate to Severe Plaque Psoriasis | 120 | 2027-02-28 |
| HS-20094 Injection NCT07156539 |
P3 | Not yet recruiting | Type 2 Diabetes | 546 | 2027-03-30 |
| HS-20094 Injection NCT07156500 |
P3 | Not yet recruiting | Type 2 Diabetes | 204 | 2027-03-30 |
| HS-10542 NCT07470762 |
P1/2 | Recruiting | Paroxysmal Nocturnal Hemoglobinuria | 50 | 2027-05-30 |
| HS-10516 + Lenvatinib NCT07097935 |
P1/2 | Recruiting | Advanced Clear Cell Renal Cell Carcinoma | 104 | 2027-07-10 |
| HS-10365 capsules NCT06147570 |
P2 | Recruiting | Nonsmall Cell Lung Cancer | 62 | 2027-08-31 |
| HS-10390 NCT07555054 |
P2 | Not yet recruiting | Chronic Kidney Disease | 182 | 2027-11-11 |
| HS-10542 NCT07474636 |
P2 | Not yet recruiting | IgAN; Immunoglobulin A Nephropathy (IgAN) | 90 | 2027-12-10 |
| HS-10566 NCT07468851 |
P1/2 | Recruiting | High-risk Non-muscle-invasive Bladder Cancer | 180 | 2028-04-30 |
| HS-10506 NCT07587385 |
P3 | Not yet recruiting | Insomnia Disorder | 732 | 2028-06-28 |
| HS-10380 NCT07759869 |
P3 | Not yet recruiting | SCHIZOPHRENIA 1 (Disorder) | 500 | 2028-07-31 |
| HS-10504 NCT07754123 |
P3 | Recruiting | Advanced or Metastatic NSCLC | 206 | 2028-08-31 |
| HS-10380 NCT07911787 |
P3 | Not yet recruiting | SCHIZOPHRENIA 1 (Disorder) | 476 | 2029-01-24 |
| HS-10506 NCT07677384 |
P3 | Not yet recruiting | Insomnia Disorder | 600 | 2029-06-30 |
| HS-10382 NCT07885293 |
P3 | Not yet recruiting | Chronic Myeloid Leukemia | 408 | 2029-07 |
| HS-10370 NCT07822542 |
P3 | Not yet recruiting | Carcinoma, Non-Small-Cell Lung | 448 | 2030-05-31 |